Form 4 for INSM INSMED Inc
Accepted 2026-05-13 16:50:00 ET · period of report 2026-05-11 · accession 0001796960-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-13 16:50 | 2026-05-11 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $17.07 | +12.9K | 96.2K | +16% | +$221.0K |
| DMT | 2026-05-13 16:50 | 2026-05-11 | INSM | Flammer Martina M.D. | Chief Medical Off | S - Sale+OE | $100.40 | -12.9K | 83.2K | -13% | -$1.30M |
| DT | 2026-05-13 16:50 | 2026-05-11 | INSM | Flammer Martina M.D. | Chief Medical Off | M - OptEx | $0.00 | -12.9K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | M | A | 12,949 | $17.07 | 96,192 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2026-05-11 | S | D | 12,119 | $100.35 | 84,073 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F2) This is the weighted average sales price representing 12,119 shares sold at prices ranging from $100.00 to $100.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 3 | Common | Common Stock | 2026-05-11 | S | D | 830 | $101.18 | 83,243 | D | — | — | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F3) This is the weighted average sales price representing 830 shares sold at prices ranging from $101.11 to $101.36 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| 4 | Derivative | Stock Option (right to buy) | 2026-05-11 | M | D | 12,949 | $0.00 | 0 | D | $17.07 · — to 2032-05-11 | 12,949 Common Stock | (F1) This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. (F4) The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |